Paras Healthcare’s ₹1,450 crore initial public offering (IPO) was fully subscribed on October 23, 2026, the third and final day of bidding, as retail investors and qualified institutional buyers (QIBs) helped push overall demand above the number of shares on offer. The issue received total bids for approximately 1.25 times the shares available, according to PTI reporting based on exchange data.
Retail investors subscribed to 1.80 times their reserved portion, while the QIB category reached 1.41 times subscription. Demand from non-institutional investors (NIIs), however, remained weaker, with their category receiving bids for only around 55% of the shares reserved for them. The IPO closed with mixed demand across investor groups as investors assessed the hospital chain’s growth plans, recent financial recovery and debt position.
Key Takeaways
- IPO fully subscribed: Paras Healthcare’s ₹1,450 crore public issue closed at approximately 1.25 times subscription on October 23.
- Retail demand: The retail category was subscribed 1.80 times.
- Institutional interest: Qualified institutional buyers subscribed 1.41 times their allotted portion.
- NII category: Non-institutional investors subscribed approximately 0.55 times.
- Issue price: The IPO price band was ₹660–₹693 per share, with a lot size of 21 shares.
- Use of funds: The ₹500 crore fresh issue is intended primarily for debt repayment, including borrowings at a wholly owned subsidiary.
- Listing date: Shares are tentatively scheduled to list on the NSE and BSE on October 28, 2026.
Paras Healthcare IPO Subscription Status on Day 3
The final subscription figures showed that demand differed substantially between investor categories. Retail investors provided a relatively strong response, while institutional demand improved on the last day of bidding.
| Investor category | Subscription on Day 3 |
|---|---|
| Qualified institutional buyers (QIBs) | 1.41x |
| Retail individual investors | 1.80x |
| Non-institutional investors (NIIs) | Approximately 0.55x |
| Overall subscription | Approximately 1.25x |
Source: PTI report via Rediff Money. Figures are based on reported exchange data.
A subscription level of 1.25 times means bids were received for approximately 25% more shares than were available in the relevant public issue. It does not mean every applicant will receive shares.
The difference between categories is also important. Retail participation exceeded the shares reserved for that group, and QIB demand crossed its allocation. The NII portion remained undersubscribed, indicating that investor appetite was not uniform across the issue.
Subscription data measures demand during the IPO window. It does not independently establish the company’s long-term business prospects or guarantee listing gains.
Paras Healthcare IPO Price, Issue Size and Important Dates
Paras Healthcare offered its shares at a price band of ₹660 to ₹693. The public issue combined a fresh issue of shares with an offer for sale by existing shareholders.
| IPO detail | Information |
|---|---|
| Total issue size | ₹1,450 crore |
| Fresh issue | ₹500 crore |
| Offer for sale (OFS) | ₹950 crore |
| Price band | ₹660–₹693 per share |
| Lot size | 21 shares |
| Minimum investment at upper price band | ₹14,553 |
| IPO opening date | October 21, 2026 |
| IPO closing date | October 23, 2026 |
| Expected allotment date | October 26, 2026 |
| Tentative listing date | October 28, 2026 |
| Stock exchanges | NSE and BSE |
Sources: Moneycontrol IPO details and The Economic Times IPO dashboard.
At the upper end of the price band, one lot of 21 shares requires ₹14,553 before any applicable charges. Applicants should check their application status and the final allotment details when the registrar publishes the results.
How Will Paras Healthcare Use the IPO Proceeds?
The distinction between the fresh issue and the offer for sale matters for investors.
The company is raising ₹500 crore through the fresh issue. According to the offer details reported by Business Standard, the company plans to use ₹320.90 crore to repay or prepay certain borrowings and invest ₹54.10 crore in its wholly owned subsidiary, Plus Medicare Hospitals Private Limited, which operates the Srinagar hospital, to help repay its debt. The remaining proceeds are intended for general corporate purposes.
The ₹950 crore offer for sale allows existing shareholders to sell part of their holdings. That money goes to the selling shareholders rather than directly to Paras Healthcare.
The company has said that reducing debt will help strengthen its balance sheet and create more financial flexibility. However, repayment of some borrowings does not mean the company will become debt-free, particularly as it plans further hospital expansion.
What Does Paras Healthcare Do?
Paras Healthcare operates hospitals under the Paras Health brand, providing tertiary and quaternary healthcare services. These include complex medical treatments and specialized care across multiple clinical departments.
As of June 30, 2026, the company operated eight hospitals with a combined capacity of 2,211 beds. Its network spans locations including Gurugram, Panchkula, Patna, Darbhanga, Kanpur, Udaipur, Ranchi and Srinagar.
The hospital chain focuses on specialties including cardiac care, oncology, neurology, gastroenterology, orthopaedics and renal care. Demand for specialized treatment, higher patient volumes and improved hospital utilization can influence revenue and profitability.
Paras Healthcare has also outlined expansion plans that include a 300-bed hospital in Gurugram and a 500-bed facility in Ludhiana. These projects could expand capacity, but new hospitals require significant capital and may take time to reach mature occupancy and profitability.
Financial Performance: Profitability Has Improved
Paras Healthcare’s financial performance improved significantly in the financial year ended March 2026, following losses in the preceding two financial years.
| Financial metric | FY2025 | FY2026 |
|---|---|---|
| Total income | ₹1,015.6 crore | ₹1,628.8 crore |
| EBITDA | ₹156.5 crore | ₹335.6 crore |
| Profit after tax | Loss of ₹58.0 crore | Profit of ₹43.8 crore |
| EBITDA margin | — | Approximately 20.6% |
Source: Paras Healthcare draft prospectus and Business Standard. Figures rounded.
The company moved from a consolidated net loss in FY2025 to a profit in FY2026, while EBITDA more than doubled. Improved operating performance can strengthen the business’s ability to service debt and fund future investment.
However, the recovery is relatively recent. Investors will want to see whether higher patient volumes, better utilization and improved margins can be sustained. Hospital expansion also introduces execution risks, because newly opened facilities may initially operate below their full capacity.
What the IPO Subscription Means for Investors
The IPO’s final subscription level shows that demand exceeded the shares available overall, but it should not be interpreted as a guarantee of strong stock-market performance.
Retail subscription of 1.80 times means the number of shares applied for in that category was higher than its allocation. In an oversubscribed category, allotment depends on the applicable allocation process, and some applicants may not receive shares.
The institutional response is another factor investors may watch, but subscription figures alone do not reveal how investors will value the company after listing. The company’s profitability, debt, valuation, hospital utilization and expansion spending will continue to matter.
Investors should also distinguish between the fresh issue and the OFS. A substantial part of the IPO consists of shares sold by existing shareholders, rather than new capital being raised by the company.
The Bigger Picture
Paras Healthcare’s IPO comes as hospital operators seek to expand capacity and meet demand for specialized medical treatment. Established hospital networks can benefit from stronger patient volumes and improved operating efficiency, but expansion requires substantial investment in facilities, staff and equipment.
The issue’s final subscription indicates that aggregate demand was sufficient to cover the offering, with retail and institutional categories subscribed above their respective allocations. The weaker NII response, recent return to profitability and continuing debt requirements remain relevant considerations for investors evaluating the business beyond the IPO window.
FAQs
1. Was the Paras Healthcare IPO fully subscribed?
Yes. The IPO closed on October 23, 2026, with overall subscription of approximately 1.25 times, according to PTI reporting based on exchange data.
2. How much was the retail subscription for Paras Healthcare IPO?
The retail individual investor category was subscribed 1.80 times on the final day of bidding.
3. What was the price band for Paras Healthcare IPO?
The price band was ₹660–₹693 per share, with a lot size of 21 shares. One lot at the upper price band required ₹14,553.
4. When will Paras Healthcare IPO shares list?
The shares are tentatively scheduled to list on the NSE and BSE on October 28, 2026. The expected allotment date is October 26, subject to the final issue schedule.
5. How will Paras Healthcare use the IPO proceeds?
The company plans to use proceeds from the ₹500 crore fresh issue primarily to repay certain borrowings and support debt repayment at its Srinagar hospital subsidiary, with the balance allocated to general corporate purposes. The ₹950 crore offer for sale proceeds go to existing shareholders.
Looking Ahead
The next milestone for applicants is the allotment process, expected on October 26, followed by the tentative stock-market listing on October 28, 2026. Investors will be watching the listing price, trading volumes and market response, but the final subscription figures alone cannot predict how the shares will perform.
Over the longer term, Paras Healthcare’s performance will depend on sustaining its return to profitability, managing debt and executing its planned capacity expansion. Investors evaluating the company should read the offer documents and assess its financial position, operating performance and valuation rather than relying solely on IPO subscription levels.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
